Get the Stockscreener App
5.87
2.65%
-0.16
After Hours:
5.95
0.08
+1.36%
Turn Therapeutics Inc stock is traded at $5.87, with a volume of 36,392.
It is down -2.65% in the last 24 hours and up +19.80% over the past month.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
See More
Previous Close:
$6.03
Open:
$6.05
24h Volume:
36,392
Relative Volume:
0.94
Market Cap:
$174.86M
Revenue:
-
Net Income/Loss:
$-1.77M
P/E Ratio:
-39.48
EPS:
-0.1487
Net Cash Flow:
$-1.46M
1W Performance:
+0.17%
1M Performance:
+19.80%
6M Performance:
+95.67%
1Y Performance:
+0.00%
1-Day Range:
$5.7907
$6.37
1-Week Range:
$5.60
$6.60
52-Week Range:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Name
Turn Therapeutics Inc
Sector
Industry
Phone
(818) 564-4011
Address
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
5.87 | 179.62M | 0 | -1.77M | -1.46M | -0.1487 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-25 | Initiated | D. Boral Capital | Buy |
Turn Therapeutics Inc Stock (TTRX) Latest News
NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads - StocksToTrade
Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Yahoo Finance Australia
Number of shareholders of Turn Therapeutics Inc. – NASDAQ:TTRX - TradingView
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Slight EPS Miss Amid Pre-Revenue Stage; Shares Rise - newsline.com
First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
TTRX Q1 2026 Earnings: Narrow EPS Miss Highlights Ongoing Development PhaseRevenue Miss Report - newsline.com
TTRX Q1 2026 Earnings: Slight EPS Miss as Company Reports Loss Per Share of -$0.026Quarterly Profit Report - newsline.com
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down - Yahoo Finance
TTRX Q1 2026 Earnings: EPS Misses Estimates, Shares Fall 4.6%Profit Margin Analysis - newsline.com
2 Software Stocks to Keep an Eye On and 1 We Turn Down - Yahoo Finance
2 Financials Stocks to Target This Week and 1 We Turn Down - Yahoo Finance
TTRX: GX-03 shows rapid, biologic-level efficacy and safety in eczema, with broad expansion plans - TradingView
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data - TipRanks
Turn Therapeutics posts positive GX-03 Phase 2 interim results, updates investor presentation - TradingView
Turn Therapeutics (NASDAQ: TTRX) details GX-03 interim data, onychomycosis plans and runway - Stock Titan
Turn Therapeutics reports interim phase 2 data for eczema drug By Investing.com - Investing.com Australia
Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch - RTTNews
Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results - Moomoo
Phase II bid Turns out safe, EASI, effective; AD topical island? - BioWorld News
Turn Therapeutics reports interim phase 2 data for eczema drug - Investing.com UK
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data - TipRanks
Turn Therapeutics’ GX-03 Shows Rapid and Significant Efficacy in Phase 2 Atopic Dermatitis Trial with Strong Safety Profile 123 - Minichart
Turn Therapeutics interim Phase 2 analysis shows rapid, deep EASI responses and favorable safety for GX-03 - TradingView
Turn Therapeutics reports interim analysis findings and adaptive optimization strategy from phase 2 GX-03 trial in moderate-to-severe atopic dermatitis - marketscreener.com
Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis - TradingView
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - The Joplin Globe
Turn Therapeutics publishes GX-03 dermatitis study results - Investing.com UK
Turn Therapeutics highlights GX-03 preclinical data in dermatitis - TipRanks
Turn Therapeutics publishes GX-03 dermatitis study results By Investing.com - Investing.com Australia
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model - Business Wire
Turn Therapeutics Inc. (TTRX) Q1 2026 Earnings: Narrow EPS Miss Overshadowed by Operational ProgressReturn On Assets - thelegaladvocate.com
TTRX Q1 2026 Earnings: Narrow Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances Pipeline - Newser
Turn Therapeutics (TTRX) Q1 2026 Earnings: Narrow EPS Miss Amid Modest Stock GainsProfit Guidance Range - Newser
Daewoong takes over Turn Bio’s longevity platform from Hanall - BioWorld News
Turn Therapeutics (TTRX) Stock Trend: +2.10% Higher, $5.11 the Next Hurdle 2026-05-21Pro Trader Picks - Newser
Turn Therapeutics to Present GX-03 Atopic Dermatitis Therapy Updates at Jefferies Global Healthcare Conference 2026 12 - Minichart
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - PharmiWeb.com
Turn Therapeutics CEO to Present at Jefferies Conference - TipRanks
Turn Therapeutics to Present at Jefferies Global Healthcare Conference June 4 - TradingView
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn to Lead Clinical and Regulatory Strategy for GX-03 Atopic Dermatitis Therapy 1 - Minichart
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03 - TipRanks
Turn Therapeutics Recruits Former FDA Commissioner Stephen Hahn to Guide Eczema Drug Development - citybiz
Turn Therapeutics appoints former FDA chief Stephen Hahn - Investing.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - Weekly Voice
Turn Therapeutics appoints former FDA chief Stephen Hahn By Investing.com - Investing.com Canada
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Turn Therapeutics (TTRX) Stock: Up +1.25%, Key Resistance at $4.26 2026-05-14Mid Cap Momentum - newser.com
Turn Therapeutics Inc Stock (TTRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):